BridgeBio Oncology Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
BBOT$2.20-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(98,560) | $(50,490) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation of property and equipment | 150 | 123 |
| Stock-based compensation | 11,098 | 1,502 |
| Change in fair value of participation right liability | — | 725 |
| Net accretion of premiums and discounts on marketable securities | 331 | (797) |
| Amortization of right-of-use assets | 227 | 112 |
| Other non-cash adjustments, net | 7 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (9,456) | (2,656) |
| Other non-current assets | (228) | (341) |
| Accounts payable | 5,355 | (1,514) |
| Accrued compensation and benefits | (1,360) | (1,082) |
| Accrued research and development liabilities | 10,890 | 11,526 |
| Accrued professional services | 1,389 | 311 |
| Operating lease liabilities | (252) | 21 |
| Other accrued liabilities | (45) | (85) |
| Balances due to and from related parties | 176 | (247) |
| Net cash used in operating activities | (80,278) | (42,892) |
| Investing activities | ||
| Maturities and sales of marketable securities | 79,575 | 83,818 |
| Purchases of marketable securities | (319,182) | (58,418) |
| Purchases of property and equipment | (71) | (393) |
| Net cash (used in) provided by investing activities | (239,678) | 25,007 |
| Financing activities | ||
| Issuance of Series B redeemable convertible preferred stock, net of issuance costs | — | 22,222 |
| Payment of deferred transaction costs | (121) | (3,670) |
| Exercise of common stock options for cash | 453 | — |
| Net cash provided by financing activities | 332 | 18,552 |
| Net decrease in cash, cash equivalents, and restricted cash | (319,624) | 667 |
| Cash, cash equivalents, and restricted cash at beginning of period | 373,819 | 30,983 |
| Cash, cash equivalents, and restricted cash at end of period | $54,195 | $31,650 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Settlement of participation right liability upon issuance of Series B redeemable convertible preferred stock | $— | $3,830 |
| Right-of-use asset recognized in exchange for operating lease liabilities | $— | $2,706 |
| Deferred de-SPAC transaction costs included in accrued professional services and other accrued liabilities | $— | $1,312 |
| Unpaid property and equipment included in accounts payable and other accrued liabilities | $— | $140 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.